Compare Cassava Sciences Inc (FLNA) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Johnson Controls International PLC — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Johnson Controls International PLC trades at $153.82 (market cap $93.74B). The key difference: Johnson Controls International PLC is far larger — about 1963.1× Cassava Sciences Inc's market cap, and Johnson Controls International PLC pays a 1.03% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | JCI | |
|---|---|---|
Market Cap | $47.75M | $93.74B |
Sector | Health | Industrials |
52-Week High | $4.64 | $154.76 |
52-Week Low | $0.87 | $103.52 |
Enterprise Value | -$34.93M | $102.58B |
Dividend Yield | — | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
JCI trades at $150.70, down 0.99% on the day, with a strong bullish technical signal from moving averages. The company reported robust Q3 2026 earnings, beating estimates with $1.42 EPS and raising full-year guidance, driven by double-digit organic sales growth and record backlog. Analyst consensus is strongly positive with a $168.25 price target and no sell ratings. Recent news highlights efficiency leadership and AI-related thermal management innovations.
The outlook remains favorable given earnings momentum and strategic positioning in high-demand sectors like data centers. Key risks include execution on growth targets and macroeconomic sensitivity. The stock presents a growth opportunity supported by fundamental strength and bullish sentiment, though valuation multiples are elevated.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
